Patients commonly reported unexplained blurred or hazy vision postoperatively that requires further investigation ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical ...

Vyznova is under clinical development by Aurion Biotechnologies and currently in Phase II for Corneal Edema. According to GlobalData, Phase II drugs for Corneal Edema does not have sufficient ...

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME) has been dosed. The company describes OCU200 as a “recombinant fusion protein that consists of ...

When this happens, fluid can build up, especially in the legs. People with heart failure may notice deep pitting in their legs when the skin is pressed (also known as pitting edema), signaling a ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...

Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, ...

4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.

In May 2023, results of a phase 2 study of 49 subjects with corneal edema were presented, showing faster visual recovery in the active treatment group (Baartman et al). Cells may be derived from ...